These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11023478)

  • 1. Ex vivo and in vitro effect of human immunodeficiency virus protease inhibitors on neutrophil apoptosis.
    Mastroianni CM; Mengoni F; Lichtner M; D'Agostino C; d'Ettorre G; Forcina G; Marzi M; Russo G; Massetti AP; Vullo V
    J Infect Dis; 2000 Nov; 182(5):1536-9. PubMed ID: 11023478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated neutrophil apoptosis in the acquired immunodeficiency syndrome.
    Pitrak DL; Tsai HC; Mullane KM; Sutton SH; Stevens P
    J Clin Invest; 1996 Dec; 98(12):2714-9. PubMed ID: 8981916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells.
    Weichold FF; Bryant JL; Pati S; Barabitskaya O; Gallo RC; Reitz MS
    J Hum Virol; 1999; 2(5):261-9. PubMed ID: 10551732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control.
    Sufka SA; Ferrari G; Gryszowka VE; Wrin T; Fiscus SA; Tomaras GD; Staats HF; Patel DD; Sempowski GD; Hellmann NS; Weinhold KJ; Hicks CB
    J Infect Dis; 2003 Apr; 187(7):1027-37. PubMed ID: 12660916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival.
    Vlahakis SR; Bren GD; Algeciras-Schimnich A; Trushin SA; Schnepple DJ; Badley AD
    Clin Pharmacol Ther; 2007 Sep; 82(3):294-9. PubMed ID: 17361127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Highly Active AntiRetroviral Therapy and cryptosporidiosis].
    Morales Gomez MA
    Parassitologia; 2004 Jun; 46(1-2):95-9. PubMed ID: 15305695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
    Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
    Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.
    Lichterfeld M; Wöhrmann A; Schmeisser N; Fätkenheuer G; Salzberger B; Wyen C; Schmitz K; Sauerbruch T; Rockstroh JK
    Eur J Med Res; 2003 Feb; 8(2):56-60. PubMed ID: 12626282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
    Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
    Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of synthetic metalloproteinase inhibitor or citrate on neutrophil chemotaxis and the respiratory burst.
    Pfister RR; Haddox JL; Sommers CI
    Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1340-9. PubMed ID: 9191597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes.
    Grigem S; Fischer-Posovszky P; Debatin KM; Loizon E; Vidal H; Wabitsch M
    Horm Metab Res; 2005 Oct; 37(10):602-9. PubMed ID: 16278782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
    Resino S; Bellón JM; Ramos JT; Gonzalez-Rivera M; de José MI; González MI; Gurbindo D; Mellado MJ; Cabrero E; Muñoz-Fernández MA
    J Antimicrob Chemother; 2004 Nov; 54(5):921-31. PubMed ID: 15472006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.
    Yerly S; Rickenbach M; Popescu M; Taffe P; Craig C; Perrin L;
    Antivir Ther; 2001 Sep; 6(3):185-9. PubMed ID: 11808753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis.
    Gaedicke S; Firat-Geier E; Constantiniu O; Lucchiari-Hartz M; Freudenberg M; Galanos C; Niedermann G
    Cancer Res; 2002 Dec; 62(23):6901-8. PubMed ID: 12460905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.